What Retatrutide (LY-3437943) is

Retatrutide (LY-3437943) belongs to the incretin-mimetic class of investigational peptides — a rapidly expanding family of injectable compounds that target the gut-hormone signaling axis to regulate appetite, gastric emptying, insulin release, and energy expenditure. The class has produced the largest weight-reduction results ever reported in metabolic drug trials, and the pipeline of second- and third-generation molecules is now some of the most closely watched research in endocrinology.

Retatrutide is a triple agonist: it simultaneously activates the GLP-1 receptor, the GIP receptor, and — critically — the glucagon receptor. That third pathway is what differentiates it from every currently-approved incretin drug and is why Phase 2 weight-loss data are so unusually high.

Mechanism of action

The class targets one or more of three receptors expressed on pancreatic β-cells, on hypothalamic neurons that regulate food intake, and on peripheral tissues that regulate energy expenditure:

• GLP-1 receptor — glucose-dependent insulin secretion, slowed gastric emptying, and central satiety signaling.
• GIP receptor — potentiation of postprandial insulin release, effects on adipose tissue insulin sensitivity, and (in the newer literature) modulation of nausea pathways that partially explain why dual/triple agonists appear better tolerated at high doses than mono-agonist regimens.
• Glucagon receptor — increased resting energy expenditure and hepatic fatty-acid oxidation, the pathway most closely associated with the outsized weight-loss magnitude of triple agonists like retatrutide.

Structurally, modern incretin peptides carry a fatty-acid side chain that binds serum albumin. Albumin binding is what extends half-life from minutes (native GLP-1, ≈ 2 minutes) to days (semaglutide ≈ 165 h, tirzepatide ≈ 120 h, retatrutide ≈ 6 days), enabling once-weekly subcutaneous dosing in clinical trials.

Published research findings

• Retatrutide — Phase 2 (Jastreboff et al., NEJM 2023, NCT04881760): 48-week mean weight reduction of approximately 24.2% at the 12 mg dose in adults with obesity and no diabetes. Adverse events were primarily gastrointestinal and titration-responsive.
• Tirzepatide — SURPASS (T2D) and SURMOUNT (obesity) trials: 72-week weight reduction of approximately 20.9% at the 15 mg dose in SURMOUNT-1.
• Semaglutide — STEP-1 (Wilding et al., NEJM 2021): 68-week weight reduction of approximately 14.9% at 2.4 mg weekly in adults with obesity.
• CagriSema — REDEFINE-1 (2024/2025 readouts): weight reduction of approximately 22.7% at 68 weeks with cagrilintide 2.4 mg + semaglutide 2.4 mg weekly.

Head-to-head data across compounds are still limited; most comparisons rely on cross-trial inference, which has known limitations (different populations, run-in periods, and titration schedules).

Dosing ranges reported in the research literature

Titration is universal in this class — every compound above starts at a very low weekly dose and steps up over 12–20 weeks to reduce gastrointestinal adverse events. Dosing figures below are reproduced from published clinical-trial protocols and are provided as literature reference only, not as protocol recommendations.

• Retatrutide (Phase 2 published protocol): 2 mg / 4 mg / 8 mg / 12 mg weekly, escalated every 4 weeks.
• Tirzepatide (SURMOUNT-1 protocol): 2.5 mg starting → 5, 7.5, 10, 12.5, 15 mg maximum, escalated every 4 weeks.
• Semaglutide (STEP-1 protocol): 0.25 mg → 0.5, 1.0, 1.7, 2.4 mg maximum, escalated every 4 weeks.
• CagriSema (REDEFINE): cagrilintide and semaglutide co-titrated to 2.4 mg / 2.4 mg weekly.

Injection is subcutaneous — abdomen, thigh, or upper arm — in published protocols.

Adverse events reported in trials

The gastrointestinal profile of the class is consistent and dose-dependent: nausea, diarrhea, constipation, decreased appetite (usually the intended effect), and occasional vomiting. Most events are mild-to-moderate and titration-responsive. Trial dropouts due to GI adverse events range roughly 4–7% across the class at highest doses.

Non-GI signals reported in one or more trials: gallbladder events, injection-site reactions, transient heart-rate elevation, and (rare) pancreatitis. Preclinical rodent thyroid C-cell findings triggered the medullary-thyroid-cancer boxed warnings on approved products; that signal has not been reproduced in humans.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing Retatrutide (LY-3437943) for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for Retatrutide (LY-3437943), cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for Retatrutide (LY-3437943)

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

Retatrutide (LY-3437943) is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards